M
Marc A. Pfeffer
Researcher at Brigham and Women's Hospital
Publications - 815
Citations - 143710
Marc A. Pfeffer is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 166, co-authored 765 publications receiving 133043 citations. Previous affiliations of Marc A. Pfeffer include Partners HealthCare & University of Miami.
Papers
More filters
Journal ArticleDOI
Association of the Trp719Arg Polymorphism in Kinesin-Like Protein 6 With Myocardial Infarction and Coronary Heart Disease in 2 Prospective Trials: The CARE and WOSCOPS Trials
Olga Iakoubova,Carmen H. Tong,Charles M. Rowland,Todd G. Kirchgessner,Bradford A. Young,Andre R. Arellano,Dov Shiffman,Marc S. Sabatine,Hannia Campos,Chris J. Packard,Marc A. Pfeffer,Thomas J. White,Eugene Braunwald,James Shepherd,James J. Devlin,Frank M. Sacks,Frank M. Sacks +16 more
TL;DR: In both the CARE and the WOSCOPS trials, carriers of the KIF6 719Arg allele had an increased risk of coronary events, and pravastatin treatment substantially reduced that risk.
Journal ArticleDOI
Aortic Diameter, Wall Stiffness, and Wave Reflection in Systolic Hypertension
Gary F. Mitchell,Paul R. Conlin,Mark E. Dunlap,Yves Lacourcière,J. Malcolm O. Arnold,Richard I. Ogilvie,Joel M. Neutel,Joseph L. Izzo,Marc A. Pfeffer +8 more
TL;DR: Among individuals with systolic hypertension, increased PP is primarily attributable to increased wall stiffness and reduced aortic diameter rather than premature wave reflection, and an inverse relation between PP and aorti diameter remained significant.
Journal ArticleDOI
New Therapeutic Options in Congestive Heart Failure: Part I
TL;DR: A review of potential future therapies for congestive heart failure can be found in this paper, where the focus is on ambulatory CHF associated with left ventricular (LV) systolic dysfunction.
Journal ArticleDOI
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
Stuart J. Pocock,John J.V. McMurray,Joanna Dobson,Salim Yusuf,Christopher B. Granger,Eric L. Michelson,Jan Östergren,Marc A. Pfeffer,Scott D. Solomon,Stefan D. Anker,Karl Swedberg +10 more
TL;DR: Weight loss and leanness are important predictors of poor prognosis in CHF and the detection of weight change, and particularly weight loss, should be considered as an adverse sign prompting further evaluation.
Journal ArticleDOI
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.
Scott D. Solomon,Madeline Murguia Rice,Kathleen A. Jablonski,Powell Jose,Michael J. Domanski,Marc S. Sabatine,Bernard J. Gersh,Jean L. Rouleau,Marc A. Pfeffer,Eugene Braunwald +9 more
TL;DR: The data suggest that reduced renal function may define a subset of patients most likely to benefit from ACE-inhibitor therapy for cardiovascular protection, and trandolapril reduced mortality in patients with reduced eGFR.